FAP and head and neck squamous cell carcinoma: RO6874281, an immunocytokine comprising of an interleukin-2 variant fused with an anti-FAP antibody, has been shown to increase T and NK cells and produce a durable response in one patient with HNSCC in a phase I trial [94].